BlackRock, Inc. 13D and 13G filings for Akebia Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Akebia Therapeutics, Inc. AKBA | BlackRock Inc. BLK | 15,197,207 7.200% | 0 (Unchanged) | Filing |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | Akebia Therapeutics, Inc. AKBA | BlackRock Inc. BLK | 15,197,207 7.200% | 10,857,181 (+250.16%) | Filing |
| 2022-07-08 4:56 pm Sale | 2022-06-30 | 13G | Akebia Therapeutics, Inc. AKBA | BlackRock Inc. BLK | 4,340,026 2.400% | -9,784,189 (-69.27%) | Filing |
| 2022-02-07 4:41 pm Purchase | 2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | BlackRock Inc. BLK | 14,124,215 8.100% | 2,726,667 (+23.92%) | Filing |
| 2021-01-28 5:56 pm Purchase | 2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | BlackRock Inc. BLK | 11,397,548 7.900% | 1,136,401 (+11.07%) | Filing |